Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferdinando Squitieri

Showing results (81-90 of 147) with videos related to

Pageof 15
Sort By:
Plos One|September 11, 2013
Tractography of the corpus callosum in Huntington's diseaseOwen Phillips, Cristina Sanchez-Castaneda, Francesca Elifani, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|April 19, 2007
Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutationsFernando Gianfrancesco, Milena Cannella, Tiziana Martino, et al.
Parkinsonism & Related Disorders|January 13, 2018
The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's diseaseDaniel Zielonka, Michał Ren, Giuseppe De Michele, et al.
Journal of Personalized Medicine|January 21, 2022
Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional ImpairmentSimone Migliore, Giulia D'Aurizio, Eugenia Scaricamazza, et al.
International Clinical Psychopharmacology|April 18, 2012
Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life InstrumentEmilie Clay, Annunziata De Nicola, Julie Dorey, et al.
Frontiers in Neuroscience|June 1, 2016
Major Superficial White Matter Abnormalities in Huntington's DiseaseOwen R Phillips, Shantanu H Joshi, Ferdinando Squitieri, et al.
Journal of Alzheimer'S Disease : JAD|July 9, 2009
Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptidesRoberta Ghidoni, Valentina Albertini, Rosanna Squitti, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 6, 2003
Aberrant A2A receptor function in peripheral blood cells in Huntington's diseaseKatia Varani, Maria P Abbracchio, Milena Cannella, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2017
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocolSimone Migliore, Giuseppe Curcio, Alessandro Couyoumdjian, et al.
The Lancet. Neurology|November 11, 2011
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trialJusto Garcia de Yebenes, Bernhard Landwehrmeyer, Ferdinando Squitieri, et al.
Pageof 15

Showing results (81-90 of 147) with videos related to

Sort By:
Pageof 15
Plos One|September 11, 2013
Tractography of the corpus callosum in Huntington's diseaseOwen Phillips, Cristina Sanchez-Castaneda, Francesca Elifani, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|April 19, 2007
Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutationsFernando Gianfrancesco, Milena Cannella, Tiziana Martino, et al.
Parkinsonism & Related Disorders|January 13, 2018
The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's diseaseDaniel Zielonka, Michał Ren, Giuseppe De Michele, et al.
Journal of Personalized Medicine|January 21, 2022
Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional ImpairmentSimone Migliore, Giulia D'Aurizio, Eugenia Scaricamazza, et al.
International Clinical Psychopharmacology|April 18, 2012
Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life InstrumentEmilie Clay, Annunziata De Nicola, Julie Dorey, et al.
Frontiers in Neuroscience|June 1, 2016
Major Superficial White Matter Abnormalities in Huntington's DiseaseOwen R Phillips, Shantanu H Joshi, Ferdinando Squitieri, et al.
Journal of Alzheimer'S Disease : JAD|July 9, 2009
Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptidesRoberta Ghidoni, Valentina Albertini, Rosanna Squitti, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 6, 2003
Aberrant A2A receptor function in peripheral blood cells in Huntington's diseaseKatia Varani, Maria P Abbracchio, Milena Cannella, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2017
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocolSimone Migliore, Giuseppe Curcio, Alessandro Couyoumdjian, et al.
The Lancet. Neurology|November 11, 2011
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trialJusto Garcia de Yebenes, Bernhard Landwehrmeyer, Ferdinando Squitieri, et al.
Pageof 15